Aldosterone antagonists vs placebo or usual care
All cardiovascular death · people with chronic kidney disease requiring dialysis
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (cardiovascular) compared with control (placebo or standard care) (moderate certainty).
1 finding from 1 review
- Aldosterone antagonists for people with chronic kidney disease requiring dialysis 2021 · Cochrane Headline outcomes onlyRR 0.37 [0.22, 0.64]6 studies · 908 participantsModerate